Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival

Fig. 1

Development of serUM-Px: In step one, biomarker candidates were identified with serum protein profiling of 84 different cancer-related proteins in a pooled sample of serum from randomly selected patients that later developed metastases and patients that did not. In step two, ELISA of identified candidates from step one was then performed in individual samples in a training cohort. The thresholds for classification into metastatic risk categories were determined with receiver operating characteristics. In step three, the final serUM-Px prognostic test was validated in an independent cohort

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us